Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.393 USD | -3.32% | +8.56% | -29.65% |
May. 09 | Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.83M |
---|---|---|---|---|---|
Net income 2024 * | -5M | Net income 2025 * | -8M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.51
x | P/E ratio 2025 * |
-1.85
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.29% |
Latest transcript on Virios Therapeutics, Inc.
1 day | -3.32% | ||
1 week | +8.56% | ||
Current month | -10.51% | ||
1 month | -10.51% | ||
3 months | +6.34% | ||
6 months | -44.59% | ||
Current year | -29.65% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Duncan
CEO | Chief Executive Officer | 59 | 17-12-31 |
Angela Walsh
DFI | Director of Finance/CFO | 58 | 20-03-31 |
Ralph Grosswald
COO | Chief Operating Officer | 55 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Thomas
BRD | Director/Board Member | 70 | 20-12-20 |
Richard Whitley
BRD | Director/Board Member | 78 | 20-12-20 |
Gregory Duncan
CEO | Chief Executive Officer | 59 | 17-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 0.4044 | -0.50% | 48 964 |
24-05-15 | 0.4065 | +6.44% | 165,607 |
24-05-14 | 0.3819 | +7.85% | 191,903 |
24-05-13 | 0.3541 | -0.23% | 89,525 |
24-05-10 | 0.3549 | -4.75% | 213,396 |
Delayed Quote Nasdaq, May 16, 2024 at 02:18 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.65% | 7.83M | |
+7.70% | 113B | |
+10.36% | 106B | |
+0.41% | 22.27B | |
-11.88% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.29% | 17.24B | |
+6.66% | 14.29B | |
+36.15% | 12.52B |
- Stock Market
- Equities
- VIRI Stock